Serological population study of the coronavirus epidemic

Serological population study of the coronavirus epidemic examines the spread of the new coronavirus in Finland, and the extent and properties of the antibody formation (immunological resistance) resulting from it. This study is being carried out by the Finnish Institute for Health and Welfare (THL) in cooperation with selected hospital districts and universities. We invite people to participate in the study based on random sampling of the population. Objectives of the study SARS-CoV-2 virus causes mostly mild but also serious and sometimes life-threatening respiratory infections (COVID-19). This infectious disease has spread to become a global pandemic and strong restrictive measures have been imposed in order to control it. The primary purpose is to obtain up-to-date information on how large a proportion of the population among different age groups and regions have developed antibodies to coronavirus. These antibodies indicate previous contact with the virus, meaning either a symptomatic or non-symptomatic coronavirus infection (seroprevalence). On the basis of this information, it will be possible to deduce the intensity, direction, and current stage of the epidemic. This information will provide a well-reasoned foundation for decisions on what measures are needed to manage the epidemic at each stage. In addition, the study will examine how long the antibodies remain and how their development relates to the severity of the infection. The study will also involve development of laboratory methods for virus antibody research and preparations for responding to new research questions that may arise during the epidemic. Participate in the study? We invite people to participate in the study based on random sampling of the population. You may take part in the study if 1) you have received a personal invitation to participate and therefore belong to the selected sample, 2) you understand the information received, 3) you do not reside in an institution or an enhanced service housing unit under 24-hour care. The study is voluntary, and you need to give written informed consent if you wish to participate. The study involves taking one blood sample and collecting register data on diseases and treatment resources related to coronavirus. If you want to participate, read carefully the information sheet you have received by mail. It provides detailed information on the study and what your participation would involve. There is also a consent form that we will ask you to sign during your study visit if you choose to participate in the study. Take the invitation letter and all its attachements with you to the study visit. Invitation to participate in the serological population study of the coronavirus epidemic and Study information leaflet (248 kt, pdf) Consent of the subject (450 kt, pdf) We also ask you to reserve an appointment in your own area, preferably within a week you received the invitation. If you experience symptoms of an acute respiratory tract infection (for example, coughing, a head cold, throat pain, fever), you must wait until two days after the symptoms have ended before you make your study visit.